TGFB1 and neoplasm: Future directions include the development of more selective and effective TGF-β inhibitors, the identification of biomarkers for predicting response to TGF-β-targeted therapy, combination therapies, and the investigation of the role of non-coding RNAs and the tumor microenvironment in regulating TGF-β signaling.